Significant Victory: NABR Praises CITES Decision on Cambodian Macaques Trade

NABR Lauds CITES Decision Regarding Cambodian Long-Tailed Macaques Trade

On February 5, 2025, the National Association for Biomedical Research (NABR) expressed strong approval of the CITES Standing Committee's recent resolution to maintain the trade of Cambodian long-tailed macaques (Macaca fascicularis). This pivotal decision underscores the importance of a scientifically rigorous review process, ensuring that future policies are founded on evidence rather than misinformation.

The CITES meeting, held in Geneva, Switzerland, saw Japan leading a formal request for the committee to postpone any immediate decisions, which was met with enthusiastic support from several nations, including the United States and Canada. Notably, there were no proponents in favor of suspending the trade based on potentially erroneous claims regarding the macaque exports from Cambodia. This highlights a collaborative international stance favoring prudence and scientific validity.

At the heart of the deliberations was the need for a comprehensive review of the data presented by Cambodia. Featured were insights emphasizing that a thorough examination of the facts should precede any drastic policy changes. Matthew R. Bailey, NABR's president, emphasized that while the implications of such decisions are substantial, reliance on factual information is paramount.

"We applaud the committee’s recognition that thoughtful, evidence-driven deliberation is crucial when addressing matters of this significance," stated Bailey. He elaborated that biomedical research heavily relies on the availability of long-tailed macaques to advance vital treatments for infectious diseases, cancer, and other pressing health challenges.

The committee's decision fosters an environment where proper assessments can take place, allowing the CITES Secretariat sufficient time to investigate and further clarify the situation in Cambodia. Importantly, this approach not only empowers a transparent and evidence-based trading process but also aligns with the ethical principles surrounding biomedical research.

Moreover, this cautious methodology grants the Committee on Natural Resources in the U.S. House of Representatives the opportunity to finalize their review, reinforcing the U.S. position of conducting thorough oversight on significant wildlife trade issues.

NABR's commitment to advocating for science-based policies is unwavering. They strive to ensure that wildlife trade decisions prioritize ethical biomedical research and medical advancements, highlighting the essential role that research animals play in scientific progress.

Launched in 1979, the NABR stands at the forefront of establishing robust public policies that govern the humanitarian use of animals in biomedical research, education, and testing. The association comprises over 340 affiliates, including universities, pharmaceutical and biotech firms, healthcare professionals, and patient advocacy groups, all dedicated to responsible and humane research practices for global health enhancements.

In conclusion, as the NABR continues its discourse with global stakeholders, it remains steadfast in its goal of promoting transparency, scientific integrity, and judicious use of research animals to pioneer life-saving medical advancements. Bailey remarked, "We are determined to uphold these values as we navigate the complexities inherent in wildlife trade and biomedical research."

For more information about the NABR and their initiatives, please visit www.nabr.org.